
Medicine & Healthcare
By TrendScope Daily Team · October 31, 2026
The FDA has approved the first medicine specifically for symptomatic dermographism, a form of chronic hives that flares up from nothing more than a scratch, a tight waistband, or a seatbelt pressing against skin. Novartis announced the approval of Rhapsido, known generically as remibrutinib, on October 7, making it the only prescription option with FDA-approved uses in both symptomatic dermographism and the more widely known chronic spontaneous urticaria, after the drug’s original approval for that condition just over a year earlier.
A Condition More Common Than Most People Realize
Symptomatic dermographism, often shortened to SD, is the most prevalent form of what doctors call chronic inducible urticaria, hives triggered by a specific physical stimulus rather than appearing spontaneously. For people with the condition, ordinary friction, scratching an itch, a backpack strap, tight clothing, can trigger raised, itchy welts within minutes. According to Novartis, more than half of SD patients remain symptomatic even while taking antihistamines, and together, SD and chronic spontaneous urticaria account for more than 90% of adults living with chronic hives. Despite how common it is, SD has had no FDA-approved, condition-specific treatment until now, leaving patients and dermatologists to rely on off-label approaches or simply manage flare-ups as they came.
Remibrutinib works differently than the injectable antibody treatments that have dominated chronic hives care, such as Xolair and Dupixent. It’s an oral Bruton’s tyrosine kinase, or BTK, inhibitor, taken as a 25-milligram pill twice daily, that blocks a signaling pathway involved in histamine release rather than targeting the immune system more broadly. Novartis says no routine laboratory monitoring is required, and the pill form offers an alternative for patients who would rather avoid a recurring injection.
What the Trial Data Showed
The approval rests on RemIND, a 52-week, placebo-controlled Phase 3 trial of 115 adults who had lived with SD for at least four months despite background antihistamine use. Participants were randomized evenly to remibrutinib or placebo for the first 24 weeks, followed by an open-label extension in which everyone received the active drug. The trial’s primary measure was a complete response on the Total FRIC Score, meaning hives were essentially eliminated under a standardized provocation test.
At week 12, 29.3% of patients on remibrutinib achieved a complete response, compared with 14.0% on placebo, a statistically significant difference. The benefit showed up fast: by week 2, the complete-response rate was already 29.3% versus just 8.8% on placebo. By week 24, those numbers had climbed to 32.8% versus 15.8%. Itch scores improved just as quickly, with remibrutinib patients reporting more than double the reduction in itch intensity compared with placebo as early as week 2. Through 24 weeks, the most common side effects, nasopharyngitis, minor bleeding, headache, nausea, and abdominal pain, mirrored what had already been seen in the drug’s chronic spontaneous urticaria trials, with no severe bleeding events reported.
“SD is a chronic, debilitating condition with historically limited treatment options.”
— Giselle Mosnaim, MD, allergist-immunologist, Endeavor Health, and lead RemIND investigator
Doctors Call It a Turning Point
Mosnaim, who led the RemIND trial, described remibrutinib as “representing a meaningful step forward for this population,” pointing to how little had changed in SD treatment for years. Lindsey Finklea, a dermatologist at the University of Texas at San Antonio and another RemIND investigator, put the milestone in similarly direct terms: “Having the first FDA-approved medicine specifically for SD marks an important change.” Both doctors emphasized that the approval gives patients and physicians a tool designed and tested for this specific condition, rather than an off-label workaround borrowed from treatments built for other kinds of hives.
Novartis says it plans to submit additional RemIND data, covering two related conditions, cold urticaria and cholinergic urticaria, to health regulators globally, suggesting the company sees room to expand remibrutinib’s reach across the broader family of inducible hives. The drug is already approved for chronic spontaneous urticaria in the European Union, the United Kingdom, and China, and Novartis is separately studying it in hidradenitis suppurativa, food allergy, and relapsing multiple sclerosis, where it recently reported positive late-stage results against an existing oral therapy.
For readers managing milder, everyday hives or itch flare-ups while they talk to a doctor about prescription options, a basic non-drowsy antihistamine allergy relief tablet remains a reasonable first line of defense, though it’s worth remembering that antihistamines alone are exactly what leaves many SD and CSU patients still symptomatic in the first place.
Quick questions
What is symptomatic dermographism?
The most common form of chronic inducible hives, where scratching or pressure on the skin causes itchy welts within minutes.
What did the FDA approve for dermographism?
Novartis’s Rhapsido (remibrutinib), announced on October 7, the first medicine specifically approved for symptomatic dermographism.
How fast did remibrutinib work in trials?
Improvement was seen as early as week 2 in trials. Treatment decisions should be made with a doctor.
Related on TrendScope Daily
- The First-Ever Treatment for Alexander Disease Is Finally Giving Families Answers
- The FDA Just Approved the First Drug That Can Functionally Cure Chronic Hepatitis B
- After a Rejection, a Duchenne Cell Therapy Gets a Second Look From the FDA
- More Medicine & Healthcare stories: browse the Medicine & Healthcare section
Bottom Line
Symptomatic dermographism has long been treated as a footnote to chronic hives care, despite affecting a huge share of patients who don’t respond fully to antihistamines. Rhapsido’s approval gives doctors a condition-specific, FDA-backed option for the first time, and the speed of its effect in trials, improvement as early as week 2, could make a real difference for patients whose daily lives are shaped by unpredictable flare-ups from ordinary friction and pressure.
As an Amazon Associate, TrendScope Daily earns from qualifying purchases made through links in this article.